Ancora Biotech, founded with the mission to develop innovative antibody biotherapeutics, focuses on creating treatments for life-threatening diseases such as B cell cancers, inflammatory and metabolic disorders, and chronic hepatitis B infections. The company's core vision is to advance clinical development support, enabling healthcare professionals to effectively treat patients with severe conditions. Their flagship product, TNB-, is a biparatopic antibody designed to boost intracellular NAD+ levels by inhibiting CD38 ecto-enzyme activity.

Notable figures associated with Ancora Biotech include leading scientists and industry experts in biotechnology and clinical development. The company has garnered significant interest from investors committed to advancing medical treatments for critical diseases. Key achievements include the successful development of TNB-, which has shown promising results in preclinical studies. Ancora Biotech's impact lies in its potential to transform the treatment landscape for various severe diseases, providing new hope for patients and healthcare providers alike.